AMGNAmgenRunning, no new patients
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
Small Cell Lung Cancer (SCLC)
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
3 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 252 (final count)
- Started
- Feb 26, 2025
- Main results expected
- Aug 10, 2029
- Fully finished
- Aug 10, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Proportion of participants with confirmed objective response to Tarlatamab
Measured over: Approximately 52 Months
Proportion of participants with complete response to Tarlatamab
Measured over: Approximately 52 Months
Proportion of participants with partial response to Tarlatamab
Measured over: Approximately 52 Months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06745323 · record last updated 2026-10-06 · checked 2026-11-09 15:47 UTC